Erasca, Inc. Common Stock
ERAS
$19.15
-10.89%
Erasca, Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, a notoriously difficult-to-treat area of oncology. The company is a niche player in the competitive biotechnology sector, distinguished by its focused pipeline of modality-agnostic programs targeting key nodes, RAS directly, and treatment escape routes within this pathway. The current investor narrative is overwhelmingly driven by clinical catalyst speculation, as evidenced by the stock's explosive price action in early 2026, which likely reflects positive data readouts or significant pipeline advancements for its lead candidates, ERAS-0015 and ERAS-4001, transforming it from a quiet development story into a high-momentum biotech play.…
ERAS
Erasca, Inc. Common Stock
$19.15
ERAS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Erasca, Inc. Common Stock's 12-month outlook, with a consensus price target around $24.89 and implied upside of +30.0% versus the current price.
Average Target
$24.89
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$15 - $25
Analyst target range
Analyst coverage for ERAS appears limited, with the provided data indicating only 3 analysts contributing to estimates, and no consensus price target or recommendation distribution is supplied in the dataset. This suggests insufficient analyst coverage is available for a definitive consensus view. Limited coverage is typical for smaller, clinical-stage biotechs and can lead to higher volatility and less efficient price discovery, as the stock is more susceptible to sentiment shifts among a smaller group of informed investors rather than a broad institutional consensus. The institutional ratings data shows a pattern of reiterated bullish sentiment from several firms in early 2026, with actions like 'Buy', 'Overweight', and 'Outperform' from JP Morgan, Guggenheim, HC Wainwright, Mizuho, and Piper Sandler, all maintaining their positive ratings through March 2026. This consistent bullish stance from the covering firms, despite the lack of a quantified average target, indicates strong institutional conviction in the company's pipeline catalysts. The absence of a wide target price range in the data prevents an analysis of bull vs. bear cases, but the unanimous positive ratings from recent months signal that the analyst community following the stock is aligned in its optimistic outlook on upcoming clinical developments.
Bulls vs Bears: ERAS Investment Factors
The bull case for ERAS is powerful but precarious, built entirely on explosive momentum and clinical optimism rather than fundamentals. The bears hold stronger fundamental evidence, highlighting the company's pre-revenue status, intense cash burn, and extreme valuation expansion after a 1,435% rally. The single most important tension is between the market's priced-in expectation of clinical success (evidenced by the PB ratio of 3.24) and the binary, high-risk nature of drug development where a single data readout could validate or destroy the current $1.05 billion market cap. The stock is a pure catalyst play where technical momentum currently outweighs traditional financial metrics, but this balance is exceptionally fragile.
Bullish
- Massive 1,435% 1-Year Price Surge: The stock has exploded from $1.06 to $21.49 over the past year, driven by positive clinical catalyst speculation for its lead programs ERAS-0015 and ERAS-4001. This 1,435% gain, vastly outperforming the SPY by 1,404 percentage points, signals a fundamental re-rating of the company's pipeline potential and overwhelming market optimism.
- Strong Technical Momentum & Relative Strength: ERAS is trading at 88.5% of its 52-week range ($1.06-$24.28) with a 34.4% gain over the past month, indicating sustained bullish pressure. Its relative strength vs. the SPY is 112.17 points over 3 months, confirming the move is driven by company-specific catalysts, not broad market trends.
- Unanimous Analyst Bullish Sentiment: Despite limited coverage (3 analysts), institutional firms including JP Morgan, Guggenheim, and Piper Sandler have reiterated 'Buy' or 'Outperform' ratings through March 2026. This consistent bullish stance from the covering analyst community reflects strong conviction in upcoming clinical developments.
- Strong Balance Sheet with Low Debt: The company has a robust liquidity position with a current ratio of 10.04 and a low debt-to-equity ratio of 0.145. This provides a financial runway to fund clinical trials without the immediate pressure of high leverage or refinancing risk.
Bearish
- Pre-Revenue with No Near-Term Profitability: The company has $0 revenue, a trailing EPS of -$0.118, and a quarterly net loss of -$29.1 million. With a forward PE of -39.68 and no gross margin, valuation is entirely speculative and dependent on distant future commercialization, making it highly vulnerable to clinical setbacks.
- Extreme Valuation Expansion & Technical Overextension: The Price-to-Book ratio has expanded from 0.97 to 3.24, and the stock trades at 88.5% of its 52-week high after a 1,435% rally. This suggests the market has priced in a high probability of success, leaving minimal margin for error and increasing risk of a sharp correction on any negative news.
- High Cash Burn & Limited Runway: The company burned -$21.7 million in operating cash flow last quarter, with a TTM free cash flow of -$95.6 million. With $74.2 million in cash, the runway is finite, likely necessitating dilutive equity financing within 12-18 months if clinical progress continues without a partnership.
- Elevated Short Interest & Volatility Risk: A short ratio of 5.31 indicates significant bearish bets, which may have contributed to the rally via a short squeeze. This creates a volatile backdrop where negative catalysts could trigger aggressive selling, while positive news could fuel further squeezes, destabilizing the price.
ERAS Technical Analysis
The stock is in a powerful, sustained uptrend, having appreciated by an extraordinary 1435% over the past year and 115.8% over the last three months. With a current price of $21.49, it is trading near the top of its 52-week range ($1.06 to $24.28), specifically at approximately 88.5% of that range, indicating strong momentum but also positioning it near potential technical resistance where profit-taking or overextension concerns may arise. Recent momentum remains exceptionally strong, with a 34.4% gain over the past month, which, while decelerating from the longer-term pace, still represents significant bullish pressure; this divergence from the even more explosive shorter-term moves (e.g., 802.9% over six months) suggests the stock may be entering a phase of consolidation within its broader uptrend rather than a reversal. Key technical support is anchored at the 52-week low of $1.06, though more relevant near-term support likely resides around recent consolidation levels in the $13-$15 range observed in March. Immediate resistance is at the 52-week high of $24.28; a decisive breakout above this level would signal a continuation of the bullish trend, while a failure could lead to a pullback. The stock's beta of 1.051 indicates its volatility is only slightly above the market, which is notable given its biotech status and massive price swings, suggesting its recent moves are driven by idiosyncratic, company-specific catalysts rather than broad sector volatility. The stock's relative strength is profound, outperforming the SPY by 1404.41 percentage points over one year and 112.17 points over three months, underscoring the dominance of its unique story over market-wide movements. The 1-month price change of 34.4% vastly outpaces the SPY's 8.7% gain, confirming the stock's independent, catalyst-driven momentum. The 52-week high of $24.28 and low of $1.06 define a massive trading range, with the current price sitting much closer to the upper bound, reflecting immense speculative interest. A beta near 1.0, coupled with a short ratio of 5.31, points to elevated short interest that may have contributed to the sharp rally through a potential short squeeze, adding another layer of technical complexity to its volatile profile.
Beta
1.05
1.05x market volatility
Max Drawdown
-31.6%
Largest decline past year
52-Week Range
$1-$24
Price range past year
Annual Return
+1277.7%
Cumulative gain past year
| Period | ERAS Return | S&P 500 |
|---|---|---|
| 1m | +27.9% | +12.8% |
| 3m | +82.4% | +2.8% |
| 6m | +711.4% | +4.0% |
| 1y | +1277.7% | +29.9% |
| ytd | +433.4% | +4.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ERAS Fundamental Analysis
Erasca is a pre-revenue biotechnology company, with quarterly revenue consistently reported as $0, reflecting its clinical-stage status where investment is focused entirely on research and development rather than commercial sales. The growth trajectory is therefore not measured by sales but by pipeline progression and cash burn, with the most recent quarterly net loss of -$29.1 million in Q4 2025 representing the current operational cost of advancing its programs. The trend in net losses shows some fluctuation, from -$30.9 million in Q1 2025 to -$33.9 million in Q2, -$30.6 million in Q3, and -$29.1 million in Q4, indicating a relatively stable, though substantial, quarterly burn rate as the company advances its clinical trials. The company is deeply unprofitable, with a trailing EPS of -$0.118 and a net margin of 0%, which is standard for a clinical-stage biotech. Gross margin is also 0% due to the absence of product sales. The focus is on the efficiency of its R&D spend, which was $23.2 million in the latest quarter, down from peaks above $33 million in 2024, potentially indicating a more targeted expenditure as programs mature. The operating loss for Q4 2025 was -$32.6 million, with an EBITDA of -$31.9 million, showing no near-term path to profitability as the company remains in a capital-intensive development phase. The balance sheet shows a strong liquidity position with a current ratio of 10.04, indicating ample short-term assets relative to liabilities. The company held $74.2 million in cash at the end of Q4 2025, but it is burning significant cash, with operating cash flow of -$21.7 million for that quarter and free cash flow TTM of -$95.6 million. The debt-to-equity ratio is a low 0.145, suggesting minimal financial leverage and reliance on equity financing. The return on equity of -38.3% and return on assets of -18.3% reflect the destructive impact of high R&D expenses on shareholder equity in the absence of revenue, which is a typical profile for the sector but underscores the binary, high-risk nature of the investment tied to clinical success.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-95583000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ERAS Overvalued?
Given that Net Income is negative (-$29.1 million for the latest quarter), the primary valuation metric selected is the Price-to-Sales (PS) ratio. However, with revenue at $0, the trailing PS ratio is 0, and no meaningful forward PS can be calculated from the provided data, making traditional sales-based multiples inapplicable. The market is therefore valuing the company purely on its pipeline potential and future cash flows, as reflected in its $1.05 billion market cap, rather than on current financials. Peer comparison using standard multiples is challenging due to the lack of revenue. The company's valuation is best understood in the context of its enterprise value relative to its clinical assets and cash runway. The provided valuation data shows a trailing EV/EBITDA of -8.01 and a forward PE of -39.68, but these negative multiples are not informative for a loss-making biotech. The absence of positive financial metrics for comparison highlights that Erasca's valuation is entirely speculative and driven by clinical milestones, not by conventional financial benchmarking against profitable industry peers. Historical context shows the stock's own valuation has skyrocketed alongside its price. For instance, the Price-to-Book (PB) ratio has expanded dramatically from 0.97 in Q1 2025 to 3.24 as of the latest data, reflecting the massive re-rating as clinical prospects improved. The trailing PE ratio has moved from deeply negative levels (e.g., -9.06 in Q4 2025) to -8.47 currently, a minor change that obscures the real story of multiple expansion on future potential. Trading near the top of its historical valuation range on virtually any metric, the current price implies the market is pricing in a high probability of clinical success and future commercialization, leaving little room for disappointment.
PE
-8.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -29x~-1x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and inherent to Erasca's business model. The company is pre-revenue with a consistent quarterly net loss averaging approximately -$30 million, burning -$21.7 million in operating cash flow per quarter. With only $74.2 million in cash, the runway is less than 4 quarters at the current burn rate, necessitating a high likelihood of dilutive equity financing within the year. Furthermore, the entire valuation rests on the success of two clinical-stage assets (ERAS-0015 and ERAS-4001); a failure in either would catastrophically impair the investment thesis as there are no commercial products to fall back on.
Market & Competitive Risks center on valuation compression and sector sentiment. After a 1,435% rally, the stock trades at a Price-to-Book of 3.24, a massive expansion from 0.97 a year ago, indicating it is priced for perfection. Any disappointment in clinical data, trial delays, or competitive announcements from other RAS/MAPK pathway players could trigger a severe de-rating. The stock's beta of 1.051 suggests its volatility is only slightly above the market, but this masks the idiosyncratic, binary-event-driven risk that dominates its price action. The high short interest (ratio of 5.31) adds a layer of technical risk, potentially amplifying downward moves.
Worst-Case Scenario involves a clinical failure or significant safety setback for a lead candidate, leading to a rapid repricing of pipeline value. This could trigger analyst downgrades, a flight of momentum investors, and a covering of short positions that no longer see upside pressure. The realistic downside could see the stock retrace a substantial portion of its gains, potentially testing the $13-$15 consolidation area from March and, in a catastrophic failure, trending toward its 52-week low of $1.06. From the current price of $21.49, a drop to the recent support near $13 would represent a loss of approximately -40%, while a fall to the 52-week low would be a catastrophic -95% loss.
